Influence of piperacillin-tazobactam on inflammatory factors in patients with acute myocardial infarction after percutaneous coronary intervention
Objective To investigate the effect of piperacillin-tazobactam treatment on inflammatory factors and myocardial enzyme spectrum in patients with acute myocardial infarction after percutaneous coronary intervention(PCI)with nosocomial infection.Methods 80 cases of acute myocardial infarction patients with nosocomial infection after PCI were enrolled and randomly divided into control group and observation group,40 cases in each group.The control group was given cefuroxime,while the observation group was given piperacillin-tazobactam.The clinical efficacy,inflammatory factors[high-sensitivity C-reactive protein(hs-CRP),matrix metalloproteinase-9(MMP-9),and interleukin-6(IL-6)],left ventricular remodeling[ventricular end-diastolic diameter(LVESD)],end-systolic diameter(LVEDD),and left ventricular ejection fraction(LVEF)],myocardial enzymes[troponin Ⅰ(cTnⅠ),creatine kinase isoenzyme(CK-MB),and creatine dehydrogenase(LDH)]and adverse reactions were compared between the 2 groups.Results Compared with control group,the total effective rate in observation group was significantly higher(P<0.05).After treatment,compared with control group,the hs-CRP,MMP-9,and IL-6,LVESD and LVEDD in observation group were significantly lower(P<0.05),the LVEF was significantly higher(P<0.05),and the cTnⅠ,CK-MB and LDH were significantly lower(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the 2 groups(P>0.05).Conclusion Piperacillin-tazobactam has a good clinical effect in patients with acute myocardial infarction after PCI and nosocomial infection.It can down-regulate inflammatory factors,relieve left ventricular remodeling,and reduce the level of myocardial enzyme spectrum indexes,with good safety.
万方数据
维普
